Chen Maobo: Hong Kong Investment Corporation has invested in more than 90 projects to date, attracting high-quality medical enterprises to settle in Hong Kong.

Hong Kong Financial Secretary Paul Chan Mo-po attended the "Hong Kong-based, Linked with the Bay Area" ceremony of the Hong Kong Investment Company and New Air-Domain Group strategic cooperation today. He said that Hong Kong's unique advantages under the "one country, two systems" policy, vibrant innovation and technology ecosystem, provide a very favorable environment for life health and medical technology companies. He pointed out that the Hong Kong Investment Company has invested in over 90 projects, covering artificial intelligence, life sciences, new energy, and green technology. In terms of life health and medical technology, from large-scale artificial intelligence models based on proteins to strategic cooperation with medical service institutions, it reflects the Hong Kong Investment Company's support for the development of various aspects of this industry chain. In fact, there is a huge demand worldwide for high-quality and efficient medical services. He mentioned that, to become an international hub for medical innovation, at least three conditions must be met. First, top-notch scientific research and university talent resources; Second, excellent medical infrastructure and sufficient clinical resources; Third, leading fundraising markets. Hong Kong has these conditions, and in some medical professional fields, its research capabilities are globally leading. He said that with the gradual solid progress of the Hong Kong Investment Company, three significant effects are expected, including: more cutting-edge science and technology enterprises will settle in Hong Kong, driving drug research and medical equipment development. With the investment traction of the Hong Kong Investment Company, biopharmaceutical enterprises will settle more intensively in Hong Kong or accelerate their development in Hong Kong. At the same time, more funds from other places will also be directed towards medical technology companies, and more cutting-edge research talents will gather in Hong Kong. He mentioned that cross-institutional and cross-disciplinary cooperation benefits society. The Hong Kong Investment Company has been actively promoting all-round cooperation between scientific enterprises, higher education institutions, and research institutions through investment, building a platform for cross-institutional and cross-disciplinary cooperation. This not only accelerates the coordinated development of the medical technology industry chain upstream, midstream, and downstream but also contributes to talent training, as well as more advanced and universal medical services. He continued to say that the Hong Kong Investment Company has chosen a medical service institution based in the Greater Bay Area as a strategic partner this time. With a population of 87 million, the Greater Bay Area has a huge demand for medical services, abundant medical resources, a complete medical technology industry chain, and a large number of high-quality talents. It can be said that here, medical innovation will find new possibilities and scenarios.